The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Thalassemia Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISTH 2022 | Long-term safety & efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia
Mehran Karimi, MD, Hematology Research Center Shiraz University of Medical Sciences, Shiraz, Iran, comments on the use and long-term safety and efficacy of hydroxyurea in patients with non-transfusion-dependent β-thalassemia, highlighting the mechanism of action of this drug. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.
